Editors' Note: This article covers a stock trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.
Colorectal cancer is the third most prevalent cancer in the US, with roughly one in 20 people diagnosed with the disease. While screening methods, such as the colonoscopy and fecal tests (FOBT/FIT) are used regularly, low patient compliance means that many people continue to be diagnosed later than ideal. However two companies, Exact Sciences (EXAS) and VolitionRx (OTCQB:VNRX) are developing very different tests which each claim to pick up cancer earlier, using more sophisticated DNA-based analysis than is currently available.
Exact Sciences was...
Only subscribers can access this article, which is part of the PRO research library covering 3,610 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: